|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
American Capital Commits $212 Million Buyout of Cambridge Major Pharmaceuticals; 30-50 New Jobs to be Created
12/28/2012 8:06:00 AM
American Capital, Ltd., a publicly traded private equity firm and global asset manager, has committed US$ 212 million in the One Stop Buyout of Germantown based Cambridge Major Laboratories, Inc. (CML), a leading global provider of complex chemistry-based outsourcing services to the pharmaceutical and biotechnology industries. CML expands American Capital's portfolio of healthcare products and services companies, which have aggregate revenues of over $600 million. American Capital's investment took the form of debt and preferred and common equity. Jefferies & Company, Inc., served as sole financial advisor to CML on the transaction. CML was a portfolio company of Arlington Capital Partners prior to American Capital's investment. CML is an active pharmaceutical ingredient (API) development and manufacturing organisation serving a broad customer base of pharmaceutical, biotech and generic drug companies. The company operates from FDA inspected facilities in the US and Europe. In 2012, the company developed and supplied over 100 APIs for drugs in the early and mid-stages of development and 14 APIs for drugs that are commercially available. The products CML manufactures span a wide range of therapeutic categories from cancer to neurology to rare genetic diseases. "CML has experienced substantial growth since inception due to the company's continued expansion of its service offerings, operations and facilities," said Kyle Bradford, principal, American Capital Buyouts Group. "As a result, CML is now a market leader across the entire spectrum of drug development and commercialization, providing services and products to customers with early-stage, late-stage and commercial compounds. The Company's market position, complex chemistry abilities, outstanding execution of its service offerings and large state-of-the-art facilities, both in the US and Europe, will allow CML to continue to meet the increased outsourcing demand from pharmaceutical and biotech companies. We look forward to working with CML's management team to substantially grow the company, both organically and through acquisitions."
|
|
|
|
|
|
|
|
|
|
|